Liqun Zhou
About
Research
Publications
2026
Rational design of immune gene therapy combinations via in vivo CRISPR activation screen of tumor microenvironment modulators.
Zhang F, Dong C, Chow R, Xin S, He E, Feng Y, Zhu L, Mirza D, Tian X, Yang L, Zhou L, Ling X, Han Q, Fan R, Chen S, Wang G. Rational design of immune gene therapy combinations via in vivo CRISPR activation screen of tumor microenvironment modulators. Cancer Discovery 2026 PMID: 41747251, DOI: 10.1158/2159-8290.cd-25-0545.Peer-Reviewed Original ResearchTherapy combinationsTumor microenvironmentAntigen presentationTCR-T cell therapyAnti-tumor immunityAnti-tumor responsesSolid tumors in vivoHostile tumor microenvironmentT cell proliferationT cell activationTumor microenvironment modulationTumors in vivoCAR-TCancer immunotherapyTumor infiltrationMetastatic tumorsTCR-TTherapeutic combinationsSolid tumorsCell therapyCo-StimulationTumorMicroenvironment modulationTNFSF9Activation of genesOR7A10 GPCR engineering boosts CAR-NK therapy against solid tumours
Yang L, Renauer P, Tang K, Saskin J, Zhou L, Zou C, Lee S, Fox M, Johnson-Noya S, Weiss B, Deng S, Fang P, Chen B, Sferruzza G, Fooladi S, Zhao K, Park D, Zhang F, Tu J, Chen J, Moliterno J, Gunel M, Peng L, Chen S. OR7A10 GPCR engineering boosts CAR-NK therapy against solid tumours. Nature 2026, 1-12. PMID: 41741641, DOI: 10.1038/s41586-026-10149-8.Peer-Reviewed Original ResearchCAR-NK cellsCAR-NKSolid tumorsG protein-coupled receptorsOrthotopic breast cancer mouse modelLong-term tumor controlBreast cancer mouse modelCAR-NK therapyPoor tumor infiltrationChemokine receptor expressionCord blood donorsHuman NK cellsCancer mouse modelSolid tumor modelsCRISPR activation screenIn vivo efficacyProtein-coupled receptorsTumor controlTumor infiltrationNK cellsSurvival benefitReceptor expressionPeripheral bloodCell therapyTumor model
2025
Cas12a-knock-in mice for multiplexed genome editing, disease modelling and immune-cell engineering
Tang K, Zhou L, Tian X, Fang S, Vandenbulcke E, Du A, Shen J, Cao H, Zhou J, Chen K, Kim H, Luo Z, Xin S, Lin S, Park D, Yang L, Zhang Y, Suzuki K, Majety M, Ling X, Lam S, Chow R, Ren P, Tao B, Li K, Codina A, Dai X, Shang X, Bai S, Nottoli T, Levchenko A, Booth C, Liu C, Fan R, Dong M, Zhou X, Chen S. Cas12a-knock-in mice for multiplexed genome editing, disease modelling and immune-cell engineering. Nature Biomedical Engineering 2025, 9: 1290-1308. PMID: 40114032, PMCID: PMC12360953, DOI: 10.1038/s41551-025-01371-2.Peer-Reviewed Original ResearchKnock-In MiceBone marrow-derived dendritic cellsCD8+ T cellsNon-viral delivery vehiclesAdeno-associated virusDisease modelsCD4+Dendritic cellsC57BL/6 backgroundT cellsConstitutive expressionB cellsLipid nanoparticlesEx vivoGenome editingMiceMultiplex genome engineeringROSA26 locusGene interaction networksMultiplex genome editingLiver tissueTargeted genome editingDiseaseDelivery vehiclesCRISPR RNA
2024
65 High-fidelity enhanced AsCas12a knock-in mice for efficient multiplexed gene editing, disease modeling and orthogonal immunogenetics
Tang K, Zhou X, Fang S, Vandenbulcke E, Du A, Shen J, Cao H, Zhou J, Chen K, Xin S, Zhou L, Lin S, Majety M, Lin X, Lam S, Chow R, Bai S, Nottoli T, Booth C, Liu C, Dong M, Chen S. 65 High-fidelity enhanced AsCas12a knock-in mice for efficient multiplexed gene editing, disease modeling and orthogonal immunogenetics. 2024, a72-a72. DOI: 10.1136/jitc-2024-sitc2024.0065.Peer-Reviewed Original ResearchSingle-cell CAR T atlas reveals type 2 function in 8-year leukaemia remission
Bai Z, Feng B, McClory S, de Oliveira B, Diorio C, Gregoire C, Tao B, Yang L, Zhao Z, Peng L, Sferruzza G, Zhou L, Zhou X, Kerr J, Baysoy A, Su G, Yang M, Camara P, Chen S, Tang L, June C, Melenhorst J, Grupp S, Fan R. Single-cell CAR T atlas reveals type 2 function in 8-year leukaemia remission. Nature 2024, 634: 702-711. PMID: 39322664, PMCID: PMC11485231, DOI: 10.1038/s41586-024-07762-w.Peer-Reviewed Original ResearchChimeric antigen receptorChimeric antigen receptor T cellsT cellsIL-4CAR T-cell dysfunctionChimeric antigen receptor T-cell productsCAR-T cell persistenceProteomic profiling of seraCAR-T cellsT cell persistenceT-cell therapyLong-term remissionT cell dysfunctionCAR-T productsType 2 cytokinesAntigen-specific activationT cell productionAssociated with patientsType 2 cellsDysfunctional subsetPotential therapeutic strategyCellular immunotherapyLeukemia remissionPatients relapseType 2 functionsCAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors
Peng L, Sferruzza G, Yang L, Zhou L, Chen S. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cellular & Molecular Immunology 2024, 21: 1089-1108. PMID: 39134804, PMCID: PMC11442786, DOI: 10.1038/s41423-024-01207-0.Peer-Reviewed Original ResearchCAR-natural killerCAR-T cellsCAR-TSolid tumorsHematologic malignanciesCell therapyChimeric antigen receptor (CAR)-T cell therapyImmuno-suppressive tumor microenvironmentCAR-T cell therapyCellular cancer immunotherapyRelapsed/refractory hematologic malignanciesCAR-NK cellsTumor traffickingAdoptive immunotherapyCell immunotherapyCellular immunotherapyCancer immunotherapyImmunotherapeutic approachesHLA compatibilityTumor microenvironmentAdult patientsImmunotherapyCombat cancerTumorMalignancyThiazolidinedione enhances the efficacy of anti-PD-1 monoclonal antibody in murine melanoma
Zhang X, Gao Y, Tang K, Li Z, Halberstam A, Zhou L, Perry R. Thiazolidinedione enhances the efficacy of anti-PD-1 monoclonal antibody in murine melanoma. AJP Endocrinology And Metabolism 2024, 326: e341-e350. PMID: 38294697, PMCID: PMC11901343, DOI: 10.1152/ajpendo.00346.2023.Peer-Reviewed Original ResearchPD-1 expressionCD8+ T cellsT cell exhaustionPD-1T cellsImmunotherapy efficacyAnti-programmed cell death protein 1Tumor-infiltrating CD8+ T cellsAnti-PD-1 monoclonal antibodyAnti-PD-1 responseAnti-PD-1 treatmentCell death protein 1Enhance immunotherapy efficacyEnhance immunotherapy responseImprove immunotherapy efficacyEfficacy of immunotherapyMurine melanoma modelTumor-bearing miceExpression of peroxisome proliferator-activated receptor gammaOverall survival timePeroxisome proliferator-activated receptor gammaEffect of obesityProliferator-activated receptor gammaHuman T cellsTreated in vitro
2023
Function and Cryo-EM structures of broadly potent bispecific antibodies against multiple SARS-CoV-2 Omicron sublineages
Ren P, Hu Y, Peng L, Yang L, Suzuki K, Fang Z, Bai M, Zhou L, Feng Y, Zou Y, Xiong Y, Chen S. Function and Cryo-EM structures of broadly potent bispecific antibodies against multiple SARS-CoV-2 Omicron sublineages. Signal Transduction And Targeted Therapy 2023, 8: 281. PMID: 37518189, PMCID: PMC10387464, DOI: 10.1038/s41392-023-01509-1.Commentaries, Editorials and LettersApplications of CRISPR technology in cellular immunotherapy
Zhou X, Renauer P, Zhou L, Fang S, Chen S. Applications of CRISPR technology in cellular immunotherapy. Immunological Reviews 2023, 320: 199-216. PMID: 37449673, PMCID: PMC10787818, DOI: 10.1111/imr.13241.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsPooled screening with next-generation gene editing tools
Zhou L, Yang L, Feng Y, Chen S. Pooled screening with next-generation gene editing tools. Current Opinion In Biomedical Engineering 2023, 28: 100479. PMID: 38222973, PMCID: PMC10786633, DOI: 10.1016/j.cobme.2023.100479.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsGene editing toolsEditing toolsFunction of genesShort palindromic repeatsPooled screensPalindromic repeatsGenetic elementsPool of cellsBiological processesPooled screeningGenetic variantsPotential targetRecent advancesGenesRepeatsPlantsSequencingMutationsAgricultural researchTherapeutic interventionsSimultaneous examinationExpressionPotential future directionsCellsPool
Academic Achievements & Community Involvement
News & Links
Get In Touch
Contacts
Email